University of Kansas Alzheimers Disease

堪萨斯大学阿尔茨海默病

• 批准号: 10655210
• 负责人: RUSSELL H. SWERDLOW
• 金额: $ 76.4万
• 依托单位: UNIVERSITY OF KANSAS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-15 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10655210
• 关键词: Accelerometer; Administrative Supplement; Adult; Aerobic Exercise; Age; Aging; Alzheimer disease prevention; Alzheimer' s Disease; Alzheimer’s disease biomarker; Amyloid; Awareness; Biological; Biological Markers; Blood specimen; Body Composition; Cause of Death; Cities; Clinical; Clinical Research; Clinical Services; Clinical Trials; Clinical assessments; Cognitive; Collaborations; Communities; DNA; Data Collection; Data Coordinating Center; Dementia; Development; Diet; Dietary Assessment; Dietary intake; Down Syndrome; Dual-Energy X-Ray Absorptiometry; Energy Metabolism; Enrollment; Food; Funding; Future; Goals; Image; Incidence; Individual; Infrastructure; Intellectual functioning disability; Interdisciplinary Study; Kansas; Left; Life Style; Magnetic Resonance Imaging; Measures; Medical center; Metabolic; Metabolism; Methods; Outcome; Participant; Pathology; Patient Recruitments; Patients; Peripheral Blood Mononuclear Cell; Persons; Pharmaceutical Preparations; Physical activity; Plasma; Positron-Emission Tomography; Program Sustainability; Registries; Research; Resources; Role; Rural Community; Sampling; Secondary to; Site; Standardization; Training; Treadmill Tests; Universities; Urban Community; Weight maintenance regimen; Wichita; aging brain; clinical center; cohort; data repository; distributed data; fitness; investigator-initiated trial; neuroimaging; outreach; prevent; ranpirnase; recruit; research clinical testing; tau Proteins; therapeutic evaluation; trial readiness

ABSTRACT Most adults with Down syndrome (DS) will develop pathology associated with Alzheimer's disease (AD) beginning at ~ age 40. By age 65 the cumulative incidence of dementia exceeds 90% and is the leading cause of death in people with DS. However, individuals with DS have traditionally been left out of many of the national ADRCs clinical cohorts and are not included in state-of-the-art trials developed to prevent, delay, or treat AD. This administrative supplement will support the University of Kansas Alzheimer’s Disease Research Center’s (KU ADRC) clinical core to develop a Down Syndrome (DS) Cohort, which will increase opportunities for the study of DS and AD at KU and beyond. Additionally, to advance the KU ADRCs scientific theme of the role of altered energy metabolism in brain aging and AD, the development of this cohort will allow us to measure metabolic outcomes (e.g. physical activity, aerobic fitness, body composition, and dietary assessment) in individuals with DS and support clinical trials testing the therapeutic potential of manipulating energy metabolism to enable new avenues of research in AD prevention and treatment in individuals with DS. Specifically, we will recruit a well characterized sample of 40 adults with DS for enrollment into collaborating studies. All participants will undergo clinical testing by our clinical core using the NACC DS module which will allow them to be enrolled in a DS registry and available for enrollment in both national cohorts and investigator-initiated trials. Secondarily, to prepare for collaboration with national cohorts and future investigator-initiated trials we will recruit 20 participants from our DS cohort to participate in a trial readiness cohort where we will collect an expanded cognitive battery, blood sample, and neuroimaging assessments (MRI, amyloid PET, and tau PET) harmonized to the methods employed in the Alzheimer’s Biomarker Consortium- Down Syndrome (ABC-DS). Additionally, we will collect metabolic factors such as physical activity, aerobic fitness, body composition, and dietary intake. Creating a dedicated infrastructure and refining our data collection capabilities will enable the KU ADRC to advance local and national studies in DS and dementia and accelerate new avenues of research into the role of metabolism in brain aging and AD in the DS patient.

摘要 大多数患有唐氏综合征（DS）的成年人将发展与阿尔茨海默病（AD）相关的病理学 从40岁开始。到65岁时，痴呆症的累积发病率超过90%，是导致老年痴呆症的主要原因。 死亡的概率。然而，患有DS的个人传统上被排除在许多国家 ADRC临床队列，未纳入为预防、延迟或治疗AD而开发的最新技术水平试验。 这一行政补充将支持堪萨斯大学阿尔茨海默病研究 中心（KU ADRC）的临床核心开发唐氏综合征（DS）队列，这将增加机会 在KU和超越DS和AD的研究。此外，为了推进KU ADRC的科学主题， 改变能量代谢在脑老化和AD中的作用，这一队列的发展将使我们能够 测量代谢结果（例如，身体活动，有氧健身，身体成分和饮食 评估），并支持临床试验测试操纵的治疗潜力 能量代谢，为DS患者的AD预防和治疗研究开辟新途径。 具体而言，我们将招募40名DS成人的良好表征样本， 合作研究。所有参与者都将接受我们的临床中心使用NACC DS进行的临床测试 模块，允许他们入组DS登记研究，并可在国家和地区注册 队列和药物启动的试验。其次，准备与国家同行合作， 在未来的药物启动试验中，我们将从DS队列中招募20名受试者参加试验 准备队列，我们将收集扩展的认知电池，血液样本和神经成像 评估（MRI，淀粉样蛋白PET和tau PET）与阿尔茨海默病中采用的方法相协调 生物标志物联盟-唐氏综合征（ABC-DS）。此外，我们将收集代谢因素，如 身体活动、有氧健身、身体成分和饮食摄入。 创建专用的基础设施和完善我们的数据收集能力将使KU ADRC将推进DS和痴呆症的地方和国家研究，并加快研究的新途径， 代谢在DS患者脑老化和AD中的作用。